Abstract
Nitric oxide (NO) releasing drugs have helped patients suffering from angina pectoris for more than a century. In the 1970s NO-sensitive guanylyl cyclase was identified as the target of NO. Since then, three different isoforms of the enzyme have been identified. All NO-releasing drugs act by binding of NO to the prosthetic heme group common to all three isoforms. They thus act all as isoform-unspecific substances. This review addresses recently developed drugs that activate NO-sensitive guanylyl cyclase independent of NOrelease. They have great potential in the treatment of angina pectoris, hypertension and erectile dysfunction. The molecular target has been validated by the successful clinical use of NO-releasing drugs for more than a century. At the same time the mode of action of these drugs is entirely new. The development of highly isoform-specific derivatives with distinct pharmacological profiles is now an open possibility with great potential.
Keywords: nitric oxide, guanylyl cyclase, glyceryl trinitrste, bay41-2272, bay41-8543, bay58-2667
Current Medicinal Chemistry
Title: Drugs that Activate Specific Nitric Oxide Sensitive Guanylyl Cyclase Isoforms Independent of Nitric Oxide Release
Volume: 10 Issue: 4
Author(s): Sonke Behrends
Affiliation:
Keywords: nitric oxide, guanylyl cyclase, glyceryl trinitrste, bay41-2272, bay41-8543, bay58-2667
Abstract: Nitric oxide (NO) releasing drugs have helped patients suffering from angina pectoris for more than a century. In the 1970s NO-sensitive guanylyl cyclase was identified as the target of NO. Since then, three different isoforms of the enzyme have been identified. All NO-releasing drugs act by binding of NO to the prosthetic heme group common to all three isoforms. They thus act all as isoform-unspecific substances. This review addresses recently developed drugs that activate NO-sensitive guanylyl cyclase independent of NOrelease. They have great potential in the treatment of angina pectoris, hypertension and erectile dysfunction. The molecular target has been validated by the successful clinical use of NO-releasing drugs for more than a century. At the same time the mode of action of these drugs is entirely new. The development of highly isoform-specific derivatives with distinct pharmacological profiles is now an open possibility with great potential.
Export Options
About this article
Cite this article as:
Behrends Sonke, Drugs that Activate Specific Nitric Oxide Sensitive Guanylyl Cyclase Isoforms Independent of Nitric Oxide Release, Current Medicinal Chemistry 2003; 10 (4) . https://dx.doi.org/10.2174/0929867033368286
DOI https://dx.doi.org/10.2174/0929867033368286 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expression and Function of Anti-Inflammatory Interleukins: The Other Side of the Vascular Response to Injury
Current Vascular Pharmacology Obstructive Sleep Apnea in Chronic Obstructive Pulmonary Disease: The Overlap Syndrome
Current Respiratory Medicine Reviews Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges
Current Vascular Pharmacology Adrenomedullin in Hypertension and Obesity
Current Hypertension Reviews Pharmacotherapy for the Metabolic Syndrome
Current Vascular Pharmacology Managing Safety Signals in Large Endpoint Trials
Current Drug Safety Menopause and its Cardiometabolic Consequences: Current Perspectives
Current Vascular Pharmacology Does Daily Dialysis Improve Hypertension in Chronic Haemodialysis Patients?
Current Hypertension Reviews Inhibitors of 11β-HSD1: A Potential Treatment for the Metabolic Syndrome
Current Topics in Medicinal Chemistry The Plasma and Tissue Kininogen-kallikrein-kinin System: Role in the Cardiovascular System
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Application of Decoy Oligonucleotides as Novel Therapeutic Strategy: A Contemporary Overview
Current Drug Discovery Technologies Treatment of Leukoaraiosis: A Futuristic View
Current Drug Targets Home Blood Pressure-guided Anticipation Management of Hypertension: Effective to the Gap Between the Guidelines and the Individualized Medicine
Current Hypertension Reviews Pregnancy, Physical Activity and Weight Control to Prevent Obesity and Future Chronic Disease Risk in Both Mother and Child
Current Women`s Health Reviews Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design Goto-kakizaki Rats: Its Suitability as Non-obese Diabetic Animal Model for Spontaneous Type 2 Diabetes Mellitus
Current Diabetes Reviews Digital Ulcers in Systemic Sclerosis – Frequency, Subtype Distribution and Clinical Outcome
Current Rheumatology Reviews Novel Anticoagulants vs Warfarin for Stroke Prevention in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Synthesis of Novel 3(N,N-dialkylamino)alkyl/phenyl Substituted Thieno [2,3-d]pyrimidinones as H1-Anti-Histaminic and Antimicrobial Agents
Current Bioactive Compounds BELFAST Centenarians: A Case of Optimal Cardiovascular Risk?
Current Pharmaceutical Design